## Clinical Context This patient has **symptomatic severe aortic regurgitation (AR)** with preserved left ventricular function (EF 55%). The presence of dyspnea on exertion and orthopnea confirms hemodynamic compromise — these are **true symptoms** attributable to AR, not incidental findings. ## ACC/AHA 2020 Guideline Recommendation **Key Point:** In **symptomatic** severe AR, aortic valve replacement (AVR) is indicated regardless of whether LV function is preserved. | Clinical Scenario | Guideline Recommendation | Class | |---|---|---| | Symptomatic severe AR (any EF) | AVR | **Class I** | | Asymptomatic severe AR + EF <55% | AVR | Class I | | Asymptomatic severe AR + EF ≥55% + severe LV dilatation | AVR | Class IIa | | Asymptomatic severe AR + EF ≥55% + no dilatation | Medical surveillance | Class I | **High-Yield:** The 2020 ACC/AHA Valvular Heart Disease Guidelines (Nishimura et al.) explicitly state that **symptomatic patients with severe AR should be referred for surgery (Class I, LOE B-NR)**, irrespective of ejection fraction, because symptoms indicate that the ventricle can no longer compensate for the volume overload. ## Why Surgery Is the Correct Next Step 1. **Symptoms are the trigger** — Dyspnea on exertion and orthopnea represent NYHA Class II–III symptoms; once symptoms develop in severe AR, medical therapy alone is insufficient and surgery is indicated. 2. **EF 55% is preserved but not reassuring** — An EF of 55% in the setting of severe AR may actually represent relative LV dysfunction, as the volume-overloaded ventricle should generate a supranormal EF; a "normal" EF in this context may underestimate true dysfunction. 3. **Medical therapy is NOT a substitute for surgery** — ACE inhibitors/ARBs are used in asymptomatic patients with severe AR who are not yet surgical candidates, or as a bridge in acute decompensation. They do not replace surgery in symptomatic chronic AR. 4. **Delay risks irreversible LV damage** — Prolonged medical management of symptomatic AR risks progressive LV dilatation and irreversible myocardial dysfunction. ## Why Other Options Are Incorrect - **Option A (Amlodipine + echo in 6 months):** Amlodipine is used for afterload reduction in asymptomatic severe AR when surgery is deferred; inappropriate here as the patient is symptomatic. - **Option C (Enalapril + serial echo):** ACE inhibitors are not guideline-recommended as definitive management for symptomatic severe AR; this approach would inappropriately delay surgery. - **Option D (Cardiac catheterization):** Coronary angiography pre-operatively is considered in patients ≥40 years or with CAD risk factors, but it is not the *most appropriate next step* — surgical referral takes priority, and catheterization can be arranged as part of pre-operative workup. **Clinical Pearl:** The cardinal rule in symptomatic severe AR: **symptoms = surgery**. Medical therapy is a bridge, not a destination. (ACC/AHA 2020 Valvular Heart Disease Guidelines; Harrison's Principles of Internal Medicine, 21e, Ch. 297)
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.